Neprilysin
Neprilysin (NEP) is a type II membrane metalloendopeptidase composed of ∼750 residues with an active site containing a zinc-binding motif (HEXXH) at the extracellular carboxyl terminal domain. Neprilysin is capable of degrading the monomeric and the oligomeric forms of Aβ peptide. Neprilysin is the dominant Aβ peptide-degrading enzyme in the brain; Neprilysin becomes inactivated and down-regulated during both the early stages of Alzheimer’s disease (AD) and aging.
Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatatory, and anti-proliferative effects.
Targets for Neprilysin
Products for Neprilysin
- Cat.No. Product Name Information
- GC16138 AHU-377 hemicalcium salt AHU-377 hemicalcium salt (AHU-377 hemicalcium salt) is a potent NEP inhibitor with an IC50 of 5 nM.
- GC10146 AHU-377(Sacubitril) AHU-377(Sacubitril) (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC50 of 5 nM.
- GC31608 Candoxatril (UK 79300) Candoxatril (UK 79300) is a neutral endopeptidase (NEP) inhibitor.
- GC11784 LCZ696 LCZ696 (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure.
- GC31267 NEP-In-1 NEP-IN-1 is a neutral endopeptidase (NEP) inhibitor with IC50 of 2 nM for dNEP.
- GC32671 NEP-IN-2 NEP-IN-2 is an inhibitor of neutral endopeptidase, used in the research of proliferation in atherosclerosis, restenosis.
- GC16768 Phosphoramidon Disodium Salt Phosphoramidon Disodium Salt is a metalloprotease inhibitor.
- GC17017 Racecadotril Potent enkephalinase inhibitor
- GC63732 Sacubitril-13C4 hemicalcium salt
- GC30786 Sacubitrilat (LBQ-657) Sacubitrilat (LBQ-657) (Desethyl Sacubitril) is an active neprilysin (NEP) inhibitor.
- GC31583 SQ28603 (SQ28,603) SQ28603 (SQ28,603) is a potent and selective inhibitor of neutral endopeptidase 3.4.24.11 (NEP), an enzyme that degrades atrial natriuretic peptide (ANP).
- GC38856 TD-0212 TFA TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP.